Приказ основних података о документу

dc.creatorLeković, Danijela
dc.creatorGotić, Mirjana
dc.creatorMilić, Nataša
dc.creatorMiljić, Predrag
dc.creatorMitrović, Mirjana
dc.creatorČokić, Vladan
dc.creatorElezović, Ivo
dc.date.accessioned2021-04-20T12:37:58Z
dc.date.available2021-04-20T12:37:58Z
dc.date.issued2014
dc.identifier.issn1357-0560
dc.identifier.urihttp://rimi.imi.bg.ac.rs/handle/123456789/550
dc.description.abstractThe current widely accepted stratification defined by age and previous thrombosis in patients with essential thrombocythemia (ET) probably deserves deeper analysis. The aim of our study was to identify additional factors at the time of diagnosis, which have an impact on the thrombosis prediction. We conducted a study of 244 consecutive ET patients with median follow-up of 83 months. We analyzed the influence of age, gender, laboratory parameters, history of previous thrombosis, spleen size, JAK2 mutation as well as cardiovascular (CV) risk factors including arterial hypertension, diabetes, active tobacco use and hyperlipidemia in the terms of thrombosis. The most important predictors of thrombosis in multivariate Cox regression model were the presence of CV risk factors (p = 0.004) and previous thrombosis (p = 0.038). Accordingly, we assigned risk scores based on multivariable analysis-derived hazard ratios (HR) to the presence of 1 CV risk factor (HR = 3.5; 1 point), gt 1 CV risk factors (HR = 8.3; 2 points) and previous thrombosis (HR = 2.0; 1 point). A final three-tiered prognostic model for thrombosis prediction was developed as low (score 0), intermediate (score 1 or 2) and high risk (score 3) (p lt 0.001). The hazard of thrombosis was 3.8 % in low-risk group, 16.7 % in the intermediate-risk group and 60 % in the high-risk group (p lt 0.001). Patients with thrombotic complications during the follow-up had a significantly shorter survival (p = 0.018). The new score based on CV risk factors and previous thrombotic events allows a better patient selection within prognostic-risk groups and improved identification of the high-risk patients for thrombosis.en
dc.publisherHumana Press Inc, Totowa
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175053/RS//
dc.rightsrestrictedAccess
dc.sourceMedical Oncology
dc.subjectThrombosisen
dc.subjectPredictionen
dc.subjectEssential thrombocythemiaen
dc.subjectCardiovascular factorsen
dc.subjectMyeloproliferative neoplasmsen
dc.titleThe importance of cardiovascular risk factors for thrombosis prediction in patients with essential thrombocythemiaen
dc.typearticle
dc.rights.licenseARR
dc.citation.issue10
dc.citation.other31(10): -
dc.citation.rankM22
dc.citation.volume31
dc.identifier.doi10.1007/s12032-014-0231-1
dc.identifier.pmid25223529
dc.identifier.scopus2-s2.0-84919921026
dc.identifier.wos000342079600046
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу